Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III LNP023 in primary IgA nephropathy
jRCT2021200039Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing LNP023 with Placebo (2 arms). Primary endpoints: Change in urine protein-to-creatinine ratio at 9 months and Annualized total eGFR slope over 24 months. Started Jun 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2021200039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200039.